Gilead Sciences Inc said an analysis showed that his antiviral remdesivir helped reduce the risk of death.
Gilead Sciences Inc said an analysis on Friday showed that his antiviral remdesivir helped reduce the risk of death in seriously ill COVID-19 patients, but warned that rigorous clinical trials were needed to confirm the benefit.
Remdesivir Was At The Forefront Of The Global Battle Against COVID-19 After Intravenous Drug Helped Shorten Hospital Recovery Times, April Data From Separate Government Trial American. This study showed a trend towards better survival for remdesivir but the difference was not statistically significant.
In the last analysis, Gilead said it analyzed data from 312 patients treated in its advanced stage study and from a separate retrospective cohort of 818 patients with similar disease characteristics and severity.
Gilead’s final stage study evaluated the safety and efficacy of the 5-day and 10-day durations of remdesivir in hospitalized patients. The study did not have a placebo comparison.
Columbia University Irving Medical Center Dr. Susan Olender said in Gilead’s statement that the analysis is based on an actual environment and is an important complement to clinical trial data, although not as robust as ‘a randomized controlled trial.
However, Dr. Walid Gellad, a professor at the University of Pittsburgh School of Medicine, called it a “joke” to compare clinical trial data with observational data and conclude anything definitive about mortality.
“Mortality in remdesivir trials has generally been lower for the control and intervention groups than for the other trials and other real-world cohorts I have seen,” Gellad said in an email.
“Real-world patients are treated in different hospitals than those in the potentially different trial and adjunct treatments. They are different.”
The results of the analysis showed that 74.4% of patients treated with remdesivir recovered on day 14 compared to 59.0% of patients receiving standard care, the company said.
The mortality rate for patients treated with remdesivir in the analysis was 7.6% on day 14, compared with 12.5% in patients not treated with remdesivir.
The US government trial in April showed that patients receiving remdesivir recovered 31% faster than those receiving placebo.
Gilead shares rose 2% to $ 76.27 in the afternoon.
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
